Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
26 mai 2021 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
30 mars 2021 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
19 janv. 2021 11h30 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
13 janv. 2021 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
15 déc. 2020 11h09 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
15 déc. 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
01 déc. 2020 12h05 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft
01 déc. 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
10 nov. 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
29 oct. 2020 09h30 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today that...